GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Shiller PE Ratio

Arena Pharmaceuticals (FRA:RN3N) Shiller PE Ratio : (As of Jun. 14, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arena Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Arena Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Shiller PE Ratio Chart

Arena Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arena Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arena Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Arena Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arena Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arena Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arena Pharmaceuticals's Shiller PE Ratio falls into.



Arena Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Arena Pharmaceuticals's E10 for the quarter that ended in Dec. 2021 is calculated as:

For example, Arena Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2021 (Change)*Current CPI (Dec. 2021)
=-2.248/117.6295*117.6295
=-2.248

Current CPI (Dec. 2021) = 117.6295.

Arena Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201203 -1.363 96.783 -1.657
201206 -0.956 96.819 -1.161
201209 -0.543 97.633 -0.654
201212 -0.762 96.871 -0.925
201303 -0.695 98.209 -0.832
201306 1.364 98.518 1.629
201309 -0.598 98.790 -0.712
201312 -0.803 98.326 -0.961
201403 -0.868 99.695 -1.024
201406 0.221 100.560 0.259
201409 -0.388 100.428 -0.454
201412 -1.216 99.070 -1.444
201503 -0.924 99.621 -1.091
201506 -0.980 100.684 -1.145
201509 -0.980 100.392 -1.148
201512 -1.193 99.792 -1.406
201603 -0.808 100.470 -0.946
201606 -0.997 101.688 -1.153
201609 -0.454 101.861 -0.524
201612 1.517 101.863 1.752
201703 -0.841 102.862 -0.962
201706 -0.685 103.349 -0.780
201709 -0.722 104.136 -0.816
201712 -0.296 104.011 -0.335
201803 -0.649 105.290 -0.725
201806 -0.556 106.317 -0.615
201809 -0.600 106.507 -0.663
201812 1.187 105.998 1.317
201903 10.709 107.251 11.745
201906 -1.097 108.070 -1.194
201909 -1.326 108.329 -1.440
201912 -1.584 108.420 -1.719
202003 -1.810 108.902 -1.955
202006 -1.430 108.767 -1.547
202009 -1.435 109.815 -1.537
202012 -1.726 109.897 -1.847
202103 -1.663 111.754 -1.750
202106 -1.992 114.631 -2.044
202109 -2.729 115.734 -2.774
202112 -2.248 117.630 -2.248

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arena Pharmaceuticals  (FRA:RN3N) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Arena Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arena Pharmaceuticals (FRA:RN3N) Business Description

Traded in Other Exchanges
N/A
Address
136 Heber Avenue, Suite 204, Park City, UT, USA, 84060
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines